Acalabrutinib Clinical Trials
37 recruitingDrug
Phase 227Phase 37Phase 16Not Applicable1Phase 41
Showing 1–20 of 37 trials
Recruiting
Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)132 enrolled1 locationNCT04002947
Recruiting
Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled196 locationsNCT06136559
Recruiting
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
AstraZeneca350 enrolled29 locationsNCT05557695
Recruiting
Phase 3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
BeOne Medicines500 enrolled24 locationsNCT07277231
Recruiting
Phase 2
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
RituximabMCLBTKi+2 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT07257055
Recruiting
Phase 4
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Heart FailureChronic Lymphocytic Leukaemia
AstraZeneca60 enrolled23 locationsNCT06651970
Recruiting
Phase 2
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
M.D. Anderson Cancer Center168 enrolled1 locationNCT04169737
Recruiting
Phase 2
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Massachusetts General Hospital40 enrolled3 locationsNCT04560322
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Small Lymphocytic LymphomaChronic Lymphocytic Leukaemia
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Phase 3
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
AbbVie170 enrolled70 locationsNCT06428019
Recruiting
Phase 2
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter Syndrome
Mayo Clinic27 enrolled3 locationsNCT05388006
Recruiting
Phase 1Phase 2
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center24 enrolled3 locationsNCT05256641
Recruiting
Phase 2
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center52 enrolled1 locationNCT05336812
Recruiting
Phase 2
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Mayo Clinic120 enrolled3 locationsNCT03516617
Recruiting
Phase 2
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Grade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma
Emory University49 enrolled1 locationNCT04883437
Recruiting
Phase 3
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.394 enrolled2 locationsNCT07377578
Recruiting
Phase 1Phase 2
Avo In R/R And Previously Untreated MCL
Mantle Cell LymphomaRefractory Lymphoma
Austin I Kim72 enrolled3 locationsNCT04855695
Recruiting
Phase 2
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCLL Variant
Zulfa Omer62 enrolled1 locationNCT07014917
Recruiting
Phase 2
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
City of Hope Medical Center40 enrolled1 locationNCT06054776
Recruiting
Phase 2
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
M.D. Anderson Cancer Center60 enrolled1 locationNCT04505254